TITLE

Selling Reputation

PUB. DATE
July 2006
SOURCE
Pharmaceutical Executive;Jul2006, Vol. 26 Issue 7, p30
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the survey which states that the physicians' interactions with drug sales representatives influenced their views of pharmaceutical companies. In a survey of 320 oncologists, it was found out that Genentech enjoyed the most positive image, followed by Amgen, Novartis, and Sanofi-Aventis. Further, the survey revealed five attributes of a drug company they considered most important, and a drug company having the dependable clinical trials topped the list.
ACCESSION #
21691344

 

Related Articles

  • Sanofi-Aventis: Avastin boosts Eloxatin chemo.  // PharmaWatch: Cancer;Mar2005, Vol. 4 Issue 3, p9 

    The article discusses the results of using Avastin with Eloxatin-based chemotherapy regimens for metastatic colorectal cancer. Sanofi-Aventis SA declared that the clinical trials made on combining the two drugs had showed positive results and provided greater hope of survival to patients. The...

  • Oncology. Noah Pines // Medical Marketing & Media;Sep2012, Vol. 47 Issue 9, p46 

    The article discusses the oncology medicine launches from the newly approved drugs for cancer. It notes that marketing executive Alexander Hardy at Roche/Genentech reveals that every medicine in development has a corresponding biomarker program. It explores the top chemotherapy and targeted...

  • Oncology. Pines, Noah // Medical Marketing & Media;Oct2011, Vol. 46 Issue 10, p38 

    The article offers information on pharmaceutical company's focus on targeted therapies for the treatment of cancer. Analyst Tim Anderson of Sanford Bernstein says that molecular understanding and targeted therapeutics is unique to oncology. It also include a table that lists the top 50 oncology...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;6/17/2006, Issue 1106, p2 

    Presents news briefs on the pharmaceutical industry as of June 17, 2006. Reports of acute and chronic pulmonary adverse reactions in association with the drug nitrofurantoin in New Zealand; Warning issued by Health Canada against the use of the Triaminic Vapour Patch, which contains camphor,...

  • IN THE PIPELINE. McGuire, Stephen // Medical Marketing & Media;Dec2005, Vol. 40 Issue 12, p52 

    The article reports that in 2006 only few pharmaceutical companies will launch their products and provides information on various drugs that are expected to be launched. According to IMS Health, nearly 30 products will be coming off patent in 2006. It has been observed that many of the products...

  • News bites.  // Pharmaceutical Technology Europe;May2009, Vol. 21 Issue 5, p8 

    The article offers news briefs related to pharmaceutical industry in Germany. Sanofi Aventis SA will acquire the generics company Medley for 500 million euro and the biopharmaceutical company BiPar Sciences Inc. A study reveals that patient recruitment takes up 23% of the total clinical trial...

  • Sanofi-Aventis subsidiary initiates Phase III breast cancer trial.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p4 

    The article reports on the Phase III trial for BSI-201 initiated by Sanofi-Aventis SA and its subsidiary BiPar Sciences Inc. It states that the trial is designed to examine the efficacy and safety of BSI-201 when it is combined with gemcitabine and carboplatin in women having metastatic triple...

  • Cancer News Round-up.  // PharmaWatch: Cancer;Mar2005, Vol. 4 Issue 3, p2 

    The article reports on the developments for cancer treatments made by several pharmaceutical companies. Genentech Inc. indicated that its Avastin therapeutic had increased the survival of patients having colorectal cancer. Sanofi-Aventis had gained an approval from the U.S. Food and Drug...

  • COMPANY SPOTLIGHT - Sanofi-Aventis Group.  // PharmaWatch: Cancer;Jan2006, Vol. 5 Issue 1, p21 

    The article presents information about the pharmaceutical company Sanofi-Aventis SA. The company specializes in cardiovascular, thrombosis, metabolic disorders, oncology, central nervous system, internal medicine and vaccines. The company's six largest-selling pharmaceutical products account for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics